Eton Pharmaceuticals (NASDAQ:ETON) announced on Monday that it has secured U.S. marketing rights for a new ultra-rare disease product candidate, further cementing its position in the specialized orphan drug market.
IDEXX Laboratories (NASDAQ:IDXX) reported fourth-quarter earnings that surpassed analyst expectations, fueled by double-digit growth in its core companion animal business and significant margin expansion.
Natera (NASDAQ:NTRA) submitted a formal application for U.S. regulatory approval of its Signatera molecular residual disease test as a companion diagnostic for bladder cancer, moving to solidify its lead in the burgeoning field of precision oncology.
Revvity (NYSE:RVTY) reported fourth-quarter and full-year 2025 results on Monday that exceeded Wall Street estimates, bolstered by resilient demand across its life sciences and diagnostics portfolios.
Alvotech (NASDAQ:ALVO) solidified its global commercialization strategy on Monday, entering into new supply and marketing agreements with Sandoz to bring a suite of biosimilar candidates to Canada, Australia, and New Zealand.
Regeneron Pharmaceuticals (NASDAQ:REGN) reported fourth-quarter earnings that surpassed Wall Street expectations, bolstered by the continued explosive growth of its blockbuster immunology drug, Dupixent.
Charter Communications (NASDAQ:CHTR) shares climbed on Friday after the cable giant reported fourth-quarter earnings that surpassed analyst expectations, even as the company continued to lose high-speed internet subscribers to wireless competitors.
Takeda Pharmaceutical (NYSE:TAK) signaled on Thursday that it is successfully weathering the peak of its generic competition woes.
Alvotech (NASDAQ:ALVO) has resolved all remaining patent litigation surrounding its biosimilar candidate for the blockbuster eye drug Eylea (aflibercept), reaching a comprehensive global licensing agreement with Regeneron Pharmaceuticals and Bayer AG.
Danaher (NYSE:DHR) reported fourth-quarter results that surpassed Wall Street estimates on Wednesday, providing a bullish outlook for 2026 that suggests the long-awaited recovery in the bioprocessing and life sciences sectors is finally taking hold.
Elevance Health (NYSE:ELV) today reported fourth-quarter and full-year 2025 results that showcased robust top-line growth, even as the company manages shifting dynamics in its Medicaid and Medicare Advantage businesses.
Humana (NYSE:HUM) shares suffered their worst rout in years Tuesday, plunging 20.6% after the Trump administration proposed a nearly flat reimbursement rate for Medicare Advantage plans in 2027, a move that blindsided Wall Street and cast a shadow over the industry’s profit outlook.
